2013 Pharmaceutical Intellectual Property Forum (PIPF)

From the labor-intensive "Made in China" to knowledge-based "Created in China", China has embarked on an innovative journey to transform itself. However, to realize the transformation, there is a prerequisite, that is the Intellectual Property Right (IPR) protection. The tracker of emerging technologies says China is poised to surpass Japan as the second-largest spender on biomedical R&D, behind the U.S., as it sets far-ranging targets for new drug development as part of its 12th Five-Year Plan. The country's total R&D investments reached a cumulative $160 billion last year and are said to be paying off with exponential increases in pharmaceutical-related patent filings, according to a report issued by Lux Research. Unlike patents in other industries, pharmaceutical patents cover products that take a very long time to develop. It takes 10–15 years on average to develop a new medicine from the earliest stages of compound discovery to final approval. IP management has become the most important protection tool for R&D innovation and patent has been proved to be the primary driver of Pharma &Biotech corporate earnings.

2013 Pharmaceutical Intellectual Property Forum (PIPF) is to be held on 27-28 November in Shanghai, China. This conference aims to provide a platform to facilitate exchange of experience, and encourage more cooperation between Pharmaceutical and Biotech Companies, Law firms and IP Agencies.You will walk away with fresh insights, tactics and tools to apply for patents, strategize your litigation techniques and remain competitive in today’s constantly changing patent landscape. Hear from experts, meet potential collaborators and gather insights to re-align your own IP strategy – only at 2013 Pharmaceutical Intellectual Property Forum (PIPF).

Conference Highlights:

• Hearing from Pfizer, Bayer, Merck, GSK, Abbott on Global and Regional Pharma IP Scene
• Navigating the Regulatory Landscape in Key Countries
• Resolving Patent Regime, Patent Cliff and Patent Licensing Issues and Learning Solutions for your Top Challenges in the Interactive and Focused Panel Discussions
• Identifying Future Opportunities in Generics and Biosimilars
• A Wide Range of Cutting-Edge Case Studies from Leading IPR Experts

Who Should Attend?

• IP Director/ Manager
• Patent Director/ Manager
• R & D Director/ Head
• Patent Attorney
• General Counsel/ Legal Counsel
• In-house Lawyer
• IP Counsel/ IP Lawyer/ Consultant
• IP Investor
• IP Owner

From:

• Pharmaceutical Companies
• Biotech Companies
• Medical Devices Companies
• Academic & Research Institutions
• Government Agencies
• Intellectual Property Agencies
• Law Firms
• Others

Why You Should Attend?

• Learn about best practices and strategies in Pharma IP
• Overcome the legal and regulatory challenges
• Learn from best practices in IP litigations to help you devise your litigation strategy
• Understand how to avoid patent infringements in clinical trials
• Benefit from excellent networking opportunities with knowledgeable and experienced IP experts
• The combination of broader, international perspectives and a deeper understanding of Chinese market